Cardio Formula

1 Coenzima Q10 previne imbatranirea prematura (Anti Aging), studiile internationale au demonstrat ca nivelul redus de Coenzima CoQ10 contribuie in mod direct la imbatranire.

2 Superioritatea la Propionil L-Carnitina fata L-Carnitina, Propionil L-Carnitina creste capacitatea de mers la pacienti cu boli vasculare periferice, studiu dublu orb placebo controlat.

Cardio Formula

Cardio Formula cu: Coenzima, Q10, Propionil L-Carnitina, L-Arginina, Taurina

Concentratia de Coenzima Q10 in mitocondrie

3. Coenzima Q10 cu activitate in mitocondria: Mitocondria uzina energetica de adenozintrifosfat (ATP) a materiei vii, activeaza producerea de Adenozintrifosfat (ATP)

Coenzima Q10 se gaseste in mitocondrii: Mitocondria uzina energetica de adenozintrifosfat (ATP) a materiei vii, activeaza producerea de adenozintrifosfat (ATP)

4. Controlul apoptozei prin nivelul de ATP - Coenzima Q10 participa prin Mitocondria la producerea de Adenozintrifosfat (ATP)

5. Mitocondria un regulator de apoptoza - moarte celulara programata

- Mitocondria cheia vietii sau mortii celulare

6. Universalitatea bolii bioenergetice, reducerea degradarii bioenergetice celulare si inbunatatirea cu terapia CoQ10 un bioenergetic in terapia Anti Aging

7. Efectul de Coenzima Q10 si antrenament in performanta fizica

8. Coenzima Q10 si exercitiu persoanelor antrenate la tineri si in virsta

9. Coenzima Q10 previne oboseala si stresul, Coenzima Q10 un produs ideal cu biodisponibilitate biologica.

10. Coenzima Q10 ca antioxidant in mitocondrii si celule cu protectia de peroxidare lipidica, CoQ10 reduce oxidarea si leziunea ADN in limfocite

Densitatea de neutralizare a radicalilor liberi

Capacitate scazuta de neutralizare a radicalilor liberi

Suficienti antioxidanti de recomandat: Acid Alfa Lipoic, Ceai Verde, Vitamina C, Glutation, Vitamin E, Carotenoizi, Coenzima Q10 sau enzime antioxidante ca superoxid dismutaza (SOD) care detoxifica radicalul superoxid, peroxidul de hidrogen (H₂O₂) si Glutation peroxidaza (GPx) care detoxifica peroxizii celulari

Spirulina alge contine superoxid dismutaza (SOD) 110000 Unitati/100g

Capacitate suficienta de neutralizare a radicalilor liberi

Antioxidantii neutralizeaza radicali liberi

Formarea de radicali liberi

11. Inbalanta redox datorita a radicalilor liberi peroxidul de hidrogen (H₂O₂) radicalul superoxid si radicalul hidroxil (OH), cu consecinte la boala Parkinson

12. Coenzima Q10 cu potential de tratament in disfunctie mitocondriala si dauna oxidativa de radicali liberi in boala Alzheimer si Parkinson

Creier sanatos	Creier cu Alzheimer

Suplimente nutritive cerebrale

13. Coenzima Q10 cu efect terapeutic biochimic in tratamentul de Alzheimer Parkinson si scleroza amiotrofica laterala

- Coenzima Q10 este o substanta vitala, un antioxidant puternic, neutralizeza radicalii liberi, ajuta la preintampinarea efectelor toxice exercitate de multe medicamente sintetice

Coenzima Q10 stabilizeaza membrana celulara.

- Coenzima Q10 ca stabilizator in membrana celulara asigura permeabilitatea membranei celulare pentru ca substantele vitale sa poata intra in celula.
Pentru a asigura aceasta functie Coenzima Q10 este depozitata in membrana celulara
- Coenzima Q10 are concentratii diferite in organe
- Concentratia cea mai mare de Coenzima Q10 se gaseste in inima, ficat si in organele cu necesar mare de energie.
- Concentratia cea mai mare de Coenzima Q9 se gaseste in Chlorella cu 14mg /100g care este transformata in ficat in Coenzima Q10.

Scaderea concentratiei de Coenzima Q10, pe masura imbatranirii

- Scaderea concentratiei de Coenzima Q10, pe masura imbatranirii

Organul	La virsta de 39-42 ani % Q10	La virsta de 77-81 ani % Q10
Inima	-31,8	-57,1
Plamin	+/- 0	-48,3
Splina	-12,8	-60,1
Ficat	-4,7	-17,2
Rinichi	-27,4	-34,7
Pancreas	-8,7	-69,0
Glanda Suprarenala	-24,2	-47,2

Tesut afectat	% Q10	Studii internationale publicate
Inima - Peretele muscular	72%	(Biofactors. 1999;9(2-4):291-9)21
Epiderma (skin)	75%	(Lipids. 1989 Jul;24(7):579-84)22
Inima	58%	(Lipids. 1989 Jul;24(7):579-84)22
Rinichi	45%	(Lipids. 1989 Jul;24(7):579-84)22
Ficat	17%	(Lipids. 1989 Jul;24(7):579-84)22
Pancreas	83%	(Lipids. 1989 Jul;24(7):579-84)22
Glanda Suprarenala	50%	(Lipids. 1989 Jul;24(7):579-84)22

Procentaj in viata cu Coenzima Q10

Inbunatatirea starii pacientiilor cu Coenzima Q10

- Coenzima Q10 reduce riscul de aparitie a bolilor cardiovasculare prin imbunatatirea oxigenarii miocardului cu 20% (rol deosebit de important bolnavilor cu infarct miocardic, insuficienta miocardica hipertensiune arteriala)

Tensiunea sistolica in scadere cu Coenzima Q10	Tensiunea diastolica in scadere cu Coenzima Q10

14. Deficienta de Coenzima Q10 la boli de inima, ca adjuvant in terapia infarctului miocardic

Coenzima Q10 la boli de inima, ca adjuvant in terapia infarctului miocardic

15. Coenzima Q10 -CoQ10 reduce frecventa la boli de cancer

16. Coenzima Q10 are un impact important in eficienta controlului glicemic a pacientilor cu diabet zaharat tip 1

17. Coenzima Q10 este imunostimulator previne imunodeficienta (HIV)

18. Coenzima Q10 previne dezvoltarea paradontozei si gingivita

19. Coenzima Q10 ajuta la preintampinarea efectelor toxice exercitate de multe medicamente sintetice

Ross Pelton si alti trei farmacisti James B. LaValle, Ernest B. Hawkins au elaborat in cartea "Drug-Induced Nutrient Depletion Handbook": Medicamentele efecte adverse - Reduc nivelul nutritional - Interfereaza absorbtia sau inhiba transportul in metabolism.

20. Coenzima Q10 cu efect pozitiv in terapia de cardiopatie coronariana

21. Vitaminei C ca antioxidant reduce colesterolul foarte important in bolile cardiovasculare

22. Vitaminei C inhiba oxidatia lipoproteinelor cu densitate mica LDL - colesterol

- Din lipsa cronica de Vitamina C peretii vasculari primesc leziuni iar efectele de reparatie a organizmului compenseaza necontrolat cresterea cu celule musculare
Depunerilor cu Lipoproteina(a) = apoa in placa aterosclerotica.

- Liproproteina(a) are efect de lipire (Adeziune) de peretii vasculari, a moleculei LDL (Low Density Lipoprotein) a depunerilor de molecule de Calciu si molecule de Zahar (glucoza).

Placa aterosclerotica cu tromb

23. Coenzima Q10 inhiba oxidatia lipoproteinelor cu densitate mica LDL - colesterol, oxidatia LDL-colesterol poarta un rol esential in patogenia aterosclerozei

- Stabilizarea peretilor vasculari cu adaos de Vitamina C, L-Lizina, L-Prolina, Condroitinsulfat important pentru producerea de colagen, elastina, suplimentar asigura producerea unui film protector de tip (Teflon), prin L-Lizina si L-Prolina (Aminoacizi).

- Alte efecte secundare sint cresterea nivelul de colesterol, scaderea tigliceridelor indicat, adaosul de Vitamina C (Ginter, Haarwood), Vitamina B3 (Altschul, Carlson, Guraker, Levie), B5 (Avogaro, Cherechi, Gadie, Beamish), B6, B12, Vitamina E, L-Carnitina (Opie)

Tensiunea arterialala (Hipertonie) persoanele fara tensiune posed in arterii o vasodilatatie (Relaxing) normala.
- Pentru scaderea tensiunii arteriale studiile stiintifice recomanda adaosul de Coenzima Q10 (Digiesi), Magneziu (Turlapaty, Widman), L-Arginina (Korbut) influenteaza favorabil scaderea tensiunii arteriale, prin Arginina care produce efectul de vasodilatatie (Relaxing).

- Cardiopatie ischemica: O reducere a concentratiei de Coenzima Q10 are cu sine o tulburare miocardica datorata unei insuficiente in fluxul sanguin coronarian cu o reducere de 20 %, cea ce are din nou ca rezultat neasigurarea oxigenarii miocardice, asigurarea cu factori bioenergetici, compenseaza insuficienta in fluxul sanguin coronarian.

- Coenzima Q10 continut in mitocondrie care este uzina energetica a materiei vii, Prof.Langsjoen P. H, Prof. Folkers K.au aratat prin adaosul de Coenzima Q10 si L-Carnitina (Dr.Ghidini) o cresterea la normal, din minusul de 20 % a fluxului sanguin coronarian.

24. Coenzima Q10 cu efect pozitiv in terapia de cardiopatie ischemica si hipertensiune

25. Coenzima Q10 are efect de protectie in ischemia miocardica

26. Chlorella cu continutul de CGF (Chlorella Growth Factor) regleaza ritmul cardiac in aritmie

27. Coenzima Q10 cu efect pozitiv un exercitiu toleranta la angina pectorala

Lezarea arterelor coronare prejudiciaza hranirea muschiului inimii, asa cum se intimpla in bolile cunoscute sub numele de angina pectorala, infarct miocardic, cardiopatie ischiemica.

28. Coenzima Q10 cu cresterea concentratiei in mitocondrie are efect de protectie cerebrala si la boala Parkinson

Coenzima Q10 la cresterea concentratiei in mitocondrie

29. Coenzima Q10 indicat la pacienti cu boli cardiace, studiu randomizat, dublu-orb, placebo controlat

- Se recomanda de la virsta de 20 de ani un adaus de Coenzima Q10 pentru micsorarea sarcinii inimii si o functie normala.

Coenzima Q10 ca supliment nutritiv

30. Coenzima Q10 are actiune anti-aritmica, studiu clinic de 24 de ore cu electrocardiografe EKG la diabetici

31. Disfunctie diastolica a miocardului si raspunsul sau cu Coenzima Q10

32. Tratamentul esential la hipertensiune cu Coenzima Q10

33. Propionil L-Carnitina cu efect terapeutic la bolile cardiovasculare: Reviu

34. Studiu control al eficacitatii terapeutice cu Propionil L-Carnitina la pacienti cu insuficienta cardiaca

35. Efectul prelungit in tratament cu Propionil L-Carnitina la infarctul miocardic

36. Propionil L-Carnitina cu efect in disfunctia miocardica

37. Hemodinamica - fiziologia circulatiei si activitatea metabolica la Propionil L-Carnitina cu suprasolicitare la hipertrofia cardiaca

38. Propionil L-Carnitina cu efect la hemodinamica - fiziologia circulatiei, capacitatea la exercitii si neurohormonal pacientiilor cu insuficienta cardiaca

39. Propionil L-Carnitina cu efect in acumularea de energie si continutul de adenin nucleotide in celulele endoteliale cardiace in timpul hipoxiei

40. Influenta a Propionil L-Carnitina de energie (ATP) metabolismului mai mult ca L-Carnitina in hipertrofia de cardiomiocite

41. Propionil L-Carnitina ca protectie de adriamicina care induce cardiomiopatie

Propionil L-Carnitina previne progresia placii de aterom

42. Propionil L-Carnitina previne progresia placii de aterom la hiperlipidemie

43. Propionil L-Carnitina inbunatateste hemodinamica la pacienti cu diabet

44. Propionil L-Carnitina inbunatateste respiratia mitocondriala in inima pacientilor cu diabet

45. Studiu cu Propionil L-Carnitina in insuficienta cardiaca cronica

46. Propionil L-Carnitina cu eficacitate terapeutice la pacienti cu insuficienta cardiaca congestiva, studiu control

47. Controlul metabolismului oxidat in volumul suprasolicitat al inimii: Efectul a Propionil L-Carnitina

48. Propionil L-Carnitina evita inrautatirea functiei renale din pricina ischemia/reperfuzie.

49. Propionil L-Carnitina in claudicatie intermitenta, studiu dublu orb placebo controlat

50. Studiu multicentru european cu Propionil L-Carnitina in claudicatia intermitenta - boala arteriala periferica a membrelor inferioare

51. Propionil L-Carnitina creste capacitatea la exercitiu si statusul functional la pacienti cu claudicatie intermitenta

52. Evaluarea eficacitatii a Propionil L-Carnitina in arteriopatia obstructiva a membrelor inferioare, studiu multicentru placebo controlat

Propionil L-Carnitina cu efect in cresterea capacitatii de performanta

53. Propionil L-Carnitina cu efect in cresterea capacitatii de performanta de mers la pacienti cu boli vasculare periferice

54. Propionil L-Carnitina cu efect in terapia de 8 - zile a circulatiei singelui subcutan si muscular la pacienti cu deficiente in microcirculatia periferica.

55. Propionil L-Carnitina inbunatateste functia endoteliala la hipertensivi, diferit de produse NO sau COX

56. Propionil L-Carnitina in tratamentul disfunctiei erectile, a depresiei, oboseli la barbati in virsta

57. Observarea preliminara la folosirea de Propionil L-Carnitina in combinatie cu sildenafil la pacienti cu disfunctie erectila si diabet

58. Propionil L-Carnitina si Acetil-L-Carnitina inbunatateste actiunea la sildenafil in tratamentul disfunctiei erectile

59. Propionil L-Carnitina in sindromul de oboseala cronica (CFS)

Bibliografie-Referinte: Cardio Formula

Informatii din bibliografia electronica la tema: Nutritie si sanatate

1. Ursini T., Gambini C., Paciaroni E., and Littarru G.P. Coenzyme Q10 treatment of heart failure in the elderly: Preliminary results. In: Biomedical and Clinical Aspects of Coenzyme Q, vol. 6 (1991) Folkers K., Yamagami T., Littarru G. P. Elsevier, Amsterdam, pp 473-480.
2. Brevetti G, Perna S, Sabba C, Rossini A, Scotto di Uccio V, Berardi E, Godi L. Superiority of L-propionylcarnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study. Department of Medicine, 2nd Medical School, University of Naples Federico II, Italy.
3. Ernster L. (1977) Facts and ideas about the function of coenzyme Q10 in the Mitochondria. In: Folkers K., Yamamura Y. (eds) Biomedical and Clinical Aspects of Coenzyme Q. Elsevier, Amsterdam, pp 15-8.
4. Richter C, Schweizer M, Cossarizza A, Franceschi C. Control of apoptosis by the cellular ATP level. Laboratory of Biochemistry I, Swiss Federal Institute of Technology (ETH), Zurich, Switzerland. FEBS Lett. 1996 Jan 8;378(2):107-10.
5. Susin SA, Zamzami N, Kroemer G. Mitochondria as regulators of apoptosis: doubt no more. Centre National de la Recherche Scientifique, Unite Propre de Recherche 420, 19 rue Guy Moquet, F-94801 Villejuif, France.Biochim Biophys Acta. 1998 Aug 10;1366(1-2):151-65.
6. Linnane AW, Kovalenko S, Gingold EB. The universality of bioenergetic disease. Age-associated cellular bioenergetic degradation and amelioration therapy. Centre for Molecular Biology and Medicine, Epworth Hospital, Richmond, Melbourne, Victoria, Australia. tlinnane@cmbm.com.au Ann N Y Acad Sci. 1998 Nov 20;854:202-13.
7. Malm C, Svensson M, Ekblom B, et al. Effects of ubiquinone-10 supplementation and high intensity training on physical performance in humans. Acta Physiol Scand 1997;161:379–84.
8. Laaksonen R, Fogelholm M, Himberg JJ, et al. Ubiquinone supplementation and exercise capacity in trained young and older men. Eur J Appl Physiol 1995;72:95–100.
9. Ghirlanda G., Oradei A., Manto A., Lippa S., Uccioli L., Caputo S., Greco A.V., Littarru G.P. (1993) Evidence of Plasma CoQ10 - Lowering Effect by HMG-CoA Reductase Inhibitors: A double blind , placebo-controlled study. Clin. Pharmocol., J. 33, 3, 226-229.
- Littarru G.P., Lippa S., Oradei A., Fiorni R.M., Mazzanti L. Metabolic and diagnostic implications of blood CoQ10 levels. In: Biomedical and Clinical Aspects of Coenzyme Q, vol. 6 (1991) Folkers K., Yamagami T., and Littarru G. P. Elsevier, Amsterdam, pp 1-555.
- Pozzi F, Longo A, Lazzarini C, Carenzi A. Formulations of ubidecarenone with improved bioavailabiltity. Eur J Pharm Biopharm. 1991; 37:243-246.
10. Ernster L., and Forsmark P Ubiquinol : an endogenous antioxidant in aerobic organisms. Seventh International Symposium on Biomedical and Clinical Aspects of Coenzyme Q10 Folkers K., et al (Eds) The Clin Inves 1993 ; Suppl 71 (8): S60-S65.
- Aryoma O. Free Radicals And Antioxidant strategies in sports.J Nutr Biochem 1994 5:370
- Lockwood K., Moesgaard S., Hanioka T., Folkers K. Apparent partial remission of breast cancer in high risk patients supplemented with nutritional antioxidants, essential fatty acids and coenzyme Q10. Mol Aspects Med 1994;15 Suppl:s231-40.
- Ingold K.U., Bowry V.W., Stocker R.Autoxidation of lipids and antioxidation by alpha-tocopherol and ubiquinol in homogeneous solution and in aqueous dispersions of lipids: unrecognized consequences of lipid particle size as exemplified by oxidation of human low density lipoprotein. Proc Natl Acad Sci U SA 1993 Jan 1;90(1):45-9.
- Lass A, Sohal RS. Effect of coenzyme Q10 and alpha-tocopherol content of mitochondria on the production of superoxide anion radicals. FASEB J. 2000; 14:87-94.
- Tomasetti M, Littaru GP, Stocker R, Alleva R. Coenzyme Q10 enrichment decreases oxidative DNA damage in human lymphocytes. Free Rad Biol Med. 1999; 27:1027-1032.
11. Berg D, Youdim MB, Riederer P. Redox imbalance. Institute for Medical Genetics, University of Tuebingen and Hertie Institute for Clinical Brain Research, 72076 Tubingen, Germany. daniela.berg@uni-tuebingen.de Cell Tissue Res. 2004 Oct;318(1):201-13. Epub 2004 Sep 10.
- Di Matteo V, Esposito E. Biochemical and therapeutic effects of antioxidants in the treatment of Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. Istituto di Ricerche Farmacologiche Mario Negri, Consorzio Mario Negri Sud, 66030 Santa Maria Imbaro (Chieti), Italy. Curr Drug Targets CNS Neurol Disord. 2003 Apr;2(2):95-107.
12. Beal MF. Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment. Department of Neurology and Neuroscience, New York Presbyterian Hospital-Weill Medical College of Cornell University, 525 East 68th Street, New York, New York 10021, USA. fbeal@med.cornell.edu J Bioenerg Biomembr. 2004 Aug;36(4):381-6.
- Beal MF. Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Department of Neurology and Neuroscience, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, New York 10021, USA. fbeal@med.cornell.edu Ann N Y Acad Sci. 2003 Jun;991:120-31.
13. Di Matteo V, Esposito E. Biochemical and therapeutic effects of antioxidants in the treatment of Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. Istituto di Ricerche Farmacologiche Mario Negri, Consorzio Mario Negri Sud, 66030 Santa Maria Imbaro (Chieti), Italy. Curr Drug Targets CNS Neurol Disord. 2003 Apr;2(2):95-107.
14. Littarru G.P., Ho L., Folkers K. (1972) Deficiency of Coenzyme Q10 in human heart disease. Part I and II. In: Internat. J. Vit. Nutr. Res., 42, n. 2, 291:42, n. 3:413.
- Mortensen S.A., Vadhanavikit S., Folkers K. (1984) Deficiency of coenzyme Q10 in myocardial failure. In: Drugs Exptl. Clin. Res., vol. X(7), pp 497-502.
- Lampertico M, Comis S. Italian multicenter study on the efficacy and safety of coenzyme Q10 as adjuvant therapy in heart failure. Clin Investig. 1993; 71 (Suppl):S129-S133.
- Hofman-Bang C, Rehnqvist N, et al. Coenzyme Q10 as an adjunctive in the treatment of chronic congestive heart failure. The Q10 study group. J Card Fail. 1995; 1: 101-107.
- Morisco C, Trimarco B, Condorelli M. Effect of coenzyme Q10 therapy in patients with congestive heart failure: a long-term multi-center randomized study. Clinic Investig. 1993; 71(Suppl):S134-S136.
- Baggio E, Gandini R, Plancher AC, et al. Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure. Mol Aspects Med. 1994; 15(Suppl):287-294.
15. Mellstedt H., Osterborg A., Nylander M., Morita M., and Folkers K. A deficiency of coenzyme Q10 (CoQ10) in conventional cancer therapy and blood levels of CoQ10 in cancer patients in Sweden. In: Eighth International Symposium on Biomedical and Clinical Aspects of Coenzyme Q (1994) The Molecular Aspects of Medicine, in print.
16. Henriksen JE, Andersen CB, Hother-Nielsen O, et al. Impact of ubiquinone (coenzyme Q10) treatment on glycaemic control, insulin requirement and well-being in patients with type 1 diabetes mellitus. Diabet Med. 1999; 16:312-318.
17. Folkers K., Langsjoen P. H., et al. (1988) Biochemical deficiencies of coenzyme Q10 in HIV-infection and the exploratory treatment. Biochemical and Biophysical Research Communications vol. 153, no. 2, pp 888-896.
- Folkers K. Critique of 30 years of research on hematopoietic and immunological activities of coenzyme Q10 and potentiality for therapy of AIDS and cancer. Med Chem Res. 1992; 2:48-60.
- Folkers K, Hanioka T, Xia L-J, et al. Coenzyme Q10 increase T4/T8 ratios of lymphocytes in ordinary subjects and relevance to patients having the AIDS related complex. Biochem Biophys Res Comm. 1991; 176:786-791
18. Hansen I.L. (1976) Bioenergetics in clinical medicine. Gingival leucocytic deficiencies of coenzyme Q10 in patients with periodontal disease. In: Research Communications in Chemical Pathology and Pharmacology, vol. 14, no. 4, pp 729-738.
- Hanioka T, Tanaka M, Oijima M, et al. Effect of topical application of coenzyme Q10 on adult periodontitis. Molec Aspects Med. 1994; 15 (suppl):S241-S248.
- Watts TLP. Coenzyme Q10 and periodontal treatment: is there any beneficial effect Br Dent J. 1995; 178:209-213
19. Folkers K., Langsjoen Per H.,Willis R., Richardson P. (1990) Lovastatin decreases coenzyme Q10 levels in humans. Proc. Natl. Acad Sci. Vol. 87, pp.8931-8934.
20. Folkers K., Vadhanavikit S., Mortensen S.A. (1985) Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q10. In: Proc. Natl. Acad. Sci., USA. vol. 82(3), pp 901-904.
- Langsjoen Per.H., Vadhanavikit S., Folkers K. (1985) Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q10. In: Proc. Natl. Acad. of Sci., U.S.A., vol. 82, pp 4240-4244.
- Langsjoen P.H., Folkers K., Lyson K., Muratsu K.Effective and safe therapy with coenzyme Q10 for cardiomyopathy. In: Klin. Wochenschr. (1988) 66:583-593.
- Langsjoen P. H., Langsjoen, P. H., Folkers, K. (1989) Long term efficacy and safety of coenzyme Q10 therapy for idiopathic dilated cardiomyopathy. In: The American Journal of Cardiology, vol. 65, pp 521 - 523.
- Poggessi L., Galanti G., Comeglio M.1991 Effect of coenzyme Q10 on left ventricular function in patients with dilative cardiomyopathy. Curr. Ther. Res. 49: 878-886.
- Hanaki Y, Sugiyama S, Ozawa T, Ohno M. Coenzyme Q10 and coronary artery disease. Clin Investig. 1993; 71 (suppl):S112-S115.
21. Johnston, C.S. "Recommendations for Vitamin C Intake," JAMA, vol. 282, no. 22 (December 1999).
- Jha, P., et al., "The Antioxidant Vitamins and Cadiovascular Disease," Ann. Of Intern. Med., vol. 123 (1995), pp. 860.
- Ginter E 1977. the Role of Vitamin C and Cholesterol, in Re-evaluation of Vitamin C Hrsg. A. Hanck und G. Ritzel, H. Huber, Bern S. 53-56
- Fidanza, A. et al. Vitamin C and cholesterol. Int. J. Vit. Nutr. Res. 1982; 23:153-171.
- Ginter, E. et al. Effect of ascorbic acid on plasma cholesterol in humans in a long-term-experiment. Int. J. Vit. Nutr. Res. 1977; 47: 123134.
- Hornig, D., Weiser, H. Ascorbic acid and cholesterol: effect of graded oral intakes on cholesterol conversion to bile acid in guinea-pigs. Expenenta 1976; 32: 687-689.
22. Jialal, I., Fuller, C.J. Effect of vitamin E, Vitamin C and beta-carotene on LDL oxidation and atherosclerosis. Canad. J. Cardiol. 1995; 11, (Suppl G): 97-103.
- Chamiec, T., Herbaczynska-Cedro, K., Ceremuzynski, L. Effects of antioxidant vitamin C and E on signal-averaged electrocardiogram in acute myocardial infarction Am. J. Cardiol.1996; 77, 4: 237-241.
23. Stocker R, Bowry VW, Frei B. Ubiquinol protects human low-density lipoprotein more efficiently against lipid peroxidation than does alpha-tocopherol. Proc Natl Acad Sci USA. 1991; 88:1646-50.
- Schaefer, E. J., et al., " Lipoprotein(a) Levels And Risk of Coronary Heart Disease in Men," J. of the Amer. Med. Assoc. vol. 271 (1994), pp. 999.
- Turley, S., "The Role of Ascorbic Acid in the Regulation of Choloesterol Metabolism and in the Pathogenesis of Atherosclerosis," Atherosclerosis, vol. 24 (1976), pp. 1.
24. Rossi E., Lombardo A., Testa M., Lippa S., Oradei A., Littarru G.P., Lucente M. Coppola E., Manzoli U. Coenzyme Q10 in ischaemic cardiopathy. In: Biomedical and Clinical Aspects of Coenzyme Q, vol. 6 (1991) Folkers K., Yamagami T., and Littarru G. P. (eds) Elsevier, Amsterdam, pp 321-326.
- Folkers K, Vadhanavikit S, Mortensen SA. Biochemical rationale and myocardial tissue data on the protective therapy of cardiomyopathy with coenzyme Q10. Proc Natl Acad Sci USA. 1985; 82:901-904.
- Fraser, G.E., "Determinants of Ischemic_Heart_Disease in the Seventh Day Adventists: A Review," Am. J. Clin. Nutr., vol. 48 (1988), pp. 833-836.
25. Langsjoen Per H., Langsjoen Peter H., Folkers K. Isolated diastolic dysfunction of the myocardium and its response to CoQ10 treatment. In: Seventh International Symposium on Biomedical and Clinical Aspects of Coenzyme Q. Folkers, K., Mortensen S.A., Littarru G.P., Yamagami T., and Lenaz G. (eds) The Clinical Investigator, (1993) 71:S 140-S 144.
- Atar D, Mortensen SA, Flachs H, Herzog WR. Coenzyme Q10 protects ischemic myocardium in an open-chart swine model. Clin Investig. 1993; 71(Suppl):S103-S111.
26. Reports from the: Kanazawa Medical University Dept. Of Serology from1985-1992 Include: Regulat ion of Heartbeat Bradycardic Effect by CGF (Chlorella Growth Factor).
27. Hiasa Y., Ishida T., Maeda T., Iwanc K., Aihara T., and Mori H. (1984) Effects of coenzyme Q10 on exercise tolerance in patients with stable angina pectoris. In: Biomedical and Clinical Aspects of Coenzyme Q, vol. 3 (1981) Folkers K., Yamamura Y., (eds) Elsevier, Amsterdam, pp 291-301.
- Kamikawa T., Kobayashi A., Yamashita T., Hayashi H.1985 Effects of coenzyme Q10 on exercise tolerance in chronic stable angina pectoris. In: Am. J. Cardiol.; 56:247-251.
28. Matthews RT, Yang L, Browne S, et al. Coenzyme Q10 administration increases mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci USA. 1998; 95:8892-8897.
- Beal MF. Bioenergetic approaches for neuroprotection in Parkinson's disease. Department of Neurology and Neuroscience, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, NY, USA. fbeal@mail.med.cornell.edu Ann Neurol. 2003;53 Suppl 3:S39-47; discussion S47-8.
29. Schneeberger W., Muller-Steinwachs J., Anda L.P., Fuchs W., Zilliken F., Lyson K., Muratsu K., and Folkers K. A clinical double blind and crossover trial with coenzyme Q10 on patients with cardiac disease. In: Biomedical and Clinical Aspects of Coenzyme Q, vol. 5 (1986) Folkers K., Yamamura Y., (eds) Elsevier, Amsterdam, pp 325-333.
- Langsjoen H.A., Langsjoen P. H., Willis R., Folkers K. (1994) Usefulness of coenzyme Q10 in clinical cardiology, a long-term study. In: Eighth International Symposium on Biomedical and Clinical Aspects of Coenzyme Q, Littarru G.P., Battino M. , Folkers K. (Eds) The Molecular Aspects of Medicine, Vol. 15 (Supplement), pp S165-S175.
- Folkers K, Mortensen SA, Littarru GP, Yamagami T, Lenaz G, eds. The biochemical and clinical aspects of coenzyme Q10. Clin Investig. 1993; 71(Suppl):S51-S178.
- Crane FL, Sun IL, Sun EE. The essential functions of coenzyme Q10. Clin Investig. 1993; 71(Suppl):S55-S59.
30. Fujioka T, Sakamoto Y, Mimura G. Clinical study of cardiac arrhythmias using a 24-hour continuous electrocardiographic recorder (5th report)--antiarrhythmic action of coenzyme Q10 in diabetics. Tohoku J Exp Med. 1983 Dec;141 Suppl:453-63.
31. Langsjoen PH, Langsjoen PH, Folkers K. Isolated diastolic dysfunction of the myocardium and its response to CoQ10 treatment. Clin Investig. 1993;71(8 Suppl):S140-4.

32. Langsjoen P, Langsjoen P, Willis R, Folkers K. Treatment of essential hypertension with coenzyme Q10. Institute for Biomedical Research, University of Texas at Austin 78712, USA. Mol Aspects Med. 1994;15 Suppl:S265-72.
33. Ferrari R, Merli E, Cicchitelli G, Mele D, Fucili A, Ceconi C. Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a review. Chair of Cardiology, University Hospital of Ferrara, Gussago (Brescia), Italy. fri@dns.unife.it Ann N Y Acad Sci. 2004 Nov;1033:79-91.
- Siliprandi N, Di Lisa F, Menabò R. Propionyl-L. Cardiovasc Drugs Ther. 1991;:17–24
34. Mancini M, Rengo F, Lingetti M, Sorrentino GP, Nolfe G. Controlled study on the therapeutic efficacy of propionyl-L-carnitine in patients with congestive heart failure. Universita degli Studi di Napoli, II Facolta di Medicina e Chirurgia, Italy. Arzneimittelforschung. 1992 Sep;42(9):1101-4.
35. Pasini E, Cargnoni A, Condorelli E, Marzo A, Lisciani R, Ferrari R. Effect of prolonged treatment with propionyl-L-carnitine on erucic acid-induced myocardial dysfunction in rats. Cattedra di Cardiologia, Universita degli Studi di Brescia, Italy. Mol Cell Biochem. 1992 Jun 26;112(2):117-23.
36. Pasini E, Comini L, Ferrari R, de Giuli F, Menotti A, Dhalla NS. Effect of propionyl-L-carnitine on experimental induced cardiomyopathy in rats. Cattedra di Cardiologia, Universita degli Studi, Brescia, Italy. Am J Cardiovasc Pathol. 1992;4(3):216-22.
37. Yang XP, Samaja M, English E, Benatti P, Tarantola M, Cardace G, Motterlini R, Micheletti R, Bianchi G. Hemodynamic and metabolic activities of propionyl-L-carnitine in rats with pressure-overload cardiac hypertrophy. Prassis Sigma-Tau Research Institute, University of Milan, Italy. J Cardiovasc Pharmacol. 1992 Jul;20(1):88-98.
38. Anand I, Chandrashekhan Y, De Giuli F, Pasini E, Mazzoletti A, Confortini R, Ferrari R. Acute and chronic effects of propionyl-L-carnitine on the hemodynamics, exercise capacity, and hormones in patients with congestive heart failure. VA Medical Center, Minneapolis, Minnesota, USA. Anand IS, Chandrashekhar Y, de Giuli F. Acute and chronic effects of propionyl-L. Cardiovasc Drugs Ther. 1998;:12:–9
39. Bertelli A, Conte A, Palmieri L, Ronca G, Segnini D, Yu G. Effect of propionyl carnitine on energy charge and adenine nucleotide content of cardiac endothelial cells during hypoxia. Institute of Biological Chemistry, University of Pisa, Italy. Int J Tissue React. 1991;13(1):37-40.
40. Torielli L, Conti F, Cinato E, Ceppi E, Anversa P, Bianchi G, Ferrari P. Alterations in energy metabolism of hypertrophied rat cardiomyocytes: influence of propionyl-L-carnitine. Prassis-Sigma Tau Research Institute, Milan, Italy. J Cardiovasc Pharmacol. 1995 Sep;26(3):372-80.
41. Sayed-Ahmed MM, Salman TM, Gaballah HE, Abou El-Naga SA, Nicolai R, Calvani M. Propionyl-L-carnitine as protector against adriamycin-induced cardiomyopathy. Pharmacology Unit, National Cancer Institute, Fum El-Khalig, Kasr El-Aini Street, Cairo, Egypt.Pharmacol Res. 2001 Jun;43(6):513-20.
42. Spagnoli LG, Orlandi A, Marino B, Mauriello A, De Angelis C, Ramacci MT. Propionyl-L-carnitine prevents the progression of atherosclerotic lesions in aged hyperlipemic rabbits. Dipartimento di Chirurgia, Universita Tor Vergata di Roma, Italia. Atherosclerosis. 1995 Apr 7;114(1):29-44.
43. Lango R, Smolenski RT, Rogowski J, Siebert J, Wujtewicz M, Slominska EM, Lysiak-Szydlowska W, Yacoub MH. Propionyl-L-carnitine improves hemodynamics and metabolic markers of cardiac perfusion during coronary surgery in diabetic patients. Department of Anesthesiology and Intensive Care, Medical University of Gdansk, Debinki, 7 80-211, Poland. rlango@amg.gda.pl Cardiovasc Drugs Ther. 2005 Aug;19(4):267-75.
44. Broderick TL, Haloftis G, Paulson DJ. L-propionylcarnitine enhancement of substrate oxidation and mitochondrial respiration in the diabetic rat heart. Midwestern University, Department of Physiology, Downers Grove, Illinois, USA. J Mol Cell Cardiol. 1996 Feb;28(2):331-40.
45. Study on propionyl-L-carnitine in chronic heart failure. Eur Heart J. 1999 Jan;20(1):70-6.
46. Mancini M, Rengo F, Lingetti M, Sorrentino GP, Nolfe G. Controlled study on the therapeutic efficacy of propionyl-L-carnitine in patients with congestive heart failure. Universita degli Studi di Napoli, II Facolta di Medicina e Chirurgia, Italy. Arzneimittelforschung. 1992 Sep;42(9):1101-4.
47. El Alaoui-Talibi Z, Guendouz A, Moravec M, Moravec J. Control of oxidative metabolism in volume-overloaded rat hearts: effect of propionyl-L-carnitine. Departement de Physiologie, Universite Claude Bernard-Lyon I, Villeurbanne, France. Am J Physiol. 1997 Apr;272(4 Pt 2):H1615-24.
48. Mister M, Noris M, Szymczuk J, Azzollini N, Aiello S, Abbate M, Trochimowicz L, Gagliardini E, Arduini A, Perico N, Remuzzi G. Propionyl-L-carnitine prevents renal function deterioration due to ischemia/reperfusion. Department of Immunology, Clinics of Organ Transplantation, Mario Negri Institute for Pharmalogical Research, Via Gavazzeni 11, 24125 Bergamo, Rome, Italy. Kidney Int. 2002 Mar;61(3):1064-78.
49. Brevetti G, Perna S, Sabba C, Martone VD, Condorelli M. Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. Department of Medicine, University Federico II, Naples, Italy. J Am Coll Cardiol. 1995 Nov 15;26(6):1411-6.
50. Brevetti G, Diehm C, Lambert D. European multicenter study on propionyl-L-carnitine in intermittent claudication. Department of Medicine, University Federico II, Napoli, Italy. brevetti@unina.it J Am Coll Cardiol. 1999 Nov 1;34(5):1618-24.
51. Hiatt WR, Regensteiner JG, Creager MA, Hirsch AT, Cooke JP, Olin JW, Gorbunov GN, Isner J, Lukjanov YV, Tsitsiashvili MS, Zabelskaya TF, Amato A. Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication. Department of Medicine, Section of Vascular Medicine, Divisions of Geriatrics and Cardiology, University of Colorado Health Sciences Center, Denver 80203, USA.
52. Coto V, D'Alessandro L, Grattarola G, Imparato L, Lingetti M, Mancini M, Nolfe G, Rengo F. Evaluation of the therapeutic efficacy and tolerability of levocarnitine propionyl in the treatment of chronic obstructive arteriopathies of the lower extremities: a multicentre controlled study vs. placebo. IV Internal Medicine Department, II Medical School, University of Naples, Italy. Drugs Exp Clin Res. 1992;18(1):29-36.
53. Barker GA, Green S, Askew CD, Green AA, Walker PJ. Effect of propionyl-L-carnitine on exercise performance in peripheral arterial disease. School of Human Movement Studies, Queensland University of Technology, Brisbane, Australia. Med Sci Sports Exerc. 2001 Sep;33(9):1415-22.
54. Bolognesi M, Amidio P, Merkel C et al: Effect of 8-day therapy with propionyl-L-carnitine on muscular and subcutaneous blood flow of the lower limbs in patients with peripheral arterial disease. Clin Physiol 1995; 15(5):417-423.
55. Bueno R, Alvarez de Sotomayor M, Perez-Guerrero C, Gomez-Amores L, Vazquez CM, Herrera MD. L-carnitine and propionyl-L-carnitine improve endothelial dysfunction in spontaneously hypertensive rats: different participation of NO and COX-products. Departamento de Farmacologia, Facultad de Farmacia, Universidad de Sevilla, C/Profesor Garcia-Gonzalez no 2. 41012 Seville, Spain. Life Sci. 2005 Sep 9;77(17):2082-97.
56. Cavallini G, Caracciolo S, Vitali G, Modenini F, Biagiotti G. Carnitine versus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging. Andrological Operative Unit, Headquarters of Societa Italiana di Studi di Medicina della Riproduzione, Bologna, Italy. Urology. 2004 Apr;63(4):641-6.
57. Gentile V, Vicini P, Prigiotti G, Koverech A, Di Silverio F. Preliminary observations on the use of propionyl-L-carnitine in combination with sildenafil in patients with erectile dysfunction and diabetes. Department of Urology U Bracci, University La Sapienza, Rome, Italy. Curr Med Res Opin. 2004 Sep;20(9):1377-84.
58. Cavallini G, Modenini F, Vitali G, Koverech A. Acetyl-L-carnitine plus propionyl-L-carnitine improve efficacy of sildenafil in treatment of erectile dysfunction after bilateral nerve-sparing radical retropubic prostatectomy. Operative Unit of Andrology, Societa Italiana di Medicina della Riproduzione, Bologna, Italy. giorgiocavallini@libero.it Urology. 2005 Nov;66(5):1080-5.
59. Vermeulen RC, Scholte HR. Exploratory open label, randomized study of acetyl- and propionylcarnitine in chronic fatigue syndrome. Research Center Amsterdam, Amsterdam, Netherlands. info@cfscentrumamsterdam.nl Psychosom Med. 2004 Mar-Apr;66(2):276-82.

Literatura:

- Sinatra, S.T., The Coenzyme Q10 Phenomenon, (New Canaan: Keats Publishing Inc., 1998)

Parerea din pasajele acestui site nu a fost independent cercetate sau confirmate.